{
  "symbol": "AMRN",
  "company_name": "Amarin Corp ADR",
  "ir_website": "https://amarincorp.com/investor-relations",
  "structured_data": [
    {
      "section_name": "Financial Reports",
      "links": [
        {
          "title": "Financial Information",
          "url": "https://amarincorp.com/investor-relations/financial-information",
          "content": "You are about to review presentations, reports, filings and/or other materials regarding Amarin Corporation plc (NASDAQ: AMRN) that contain time-sensitive information.\n\nThe information contained therein is only current as of the date thereof and may not be a complete listing of all documents filed with the Securities Exchange Commission, made public or provided to Amarin shareholders.\n\nAmarin expressly disclaims any obligation to review, update or correct these materials after the date thereof. Amarin may update, amend, supplement or otherwise alter the information contained in any such materials by subsequent presentations, reports, filings, or other means without notice.\n\nCertain statements made on this web site or in materials accessed in or through the investor relations section of our web site are \"forward-looking statements,\" which are subject to risks and uncertainties, and Amarin's actual results may differ (possibly materially) from those indicated in such statements. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q.\n\nThis website is not an offer or a solicitation to buy or sell securities. Please be aware that decisions regarding investments are the responsibility of users. Although this website includes information regarding pharmaceuticals (including products under development), the information is not intended as any advertisement and/or medical advice.\n\nThis information is intended for communication with investors and should not be construed as marketing the use of any Amarin products or product candidates.\n\nInformation on this website may be revised without any prior notice.\n\nCONTINUE\n\nCANCEL\n\nGet in touch\n\nWhether you’re a patient, a healthcare professional or a job seeker, you can find the best way to contact us from the options below. We’d love to hear from you:\n\n[How to contact us](/global-login?next=%2Finvestor-relations%2Ffinancial-information#)\n\n[Report adverse event](/global-login?next=%2Finvestor-relations%2Ffinancial-information#)\n\nFollow us\n\nFollow Amarin on our social channels for the latest company news, product campaigns and industry updates:\n\n[](https://twitter.com/Amarincorp)\n\n[](https://www.linkedin.com/company/amarin-corporation/)\n\n[](https://www.youtube.com/@amarin-corporation)\n\n[About Amarin](/about-amarin)\n\n[\n  * Our Vision](/about-amarin/vision)[\n  * Our History](/about-amarin/company-history)[\n  * Where we are](/about-amarin/where-to-find-us)[\n  * Company Profile](/about-amarin/company-profile)\n\n\n[Science & Health](/science-health)\n\n[\n  * CV Health](/science-health/cv-health)[\n  * Pipeline](/science-health/our-pipeline)[\n  * Our Product](/science-health/our-product)\n\n\n[Investor Relations](/investor-relations)\n\n[\n  * Financial Information](/investor-relations/financial-information)[\n  * Analyst Coverage](/investor-relations/analyst-coverage)[\n  * Corporate Governance](/investor-relations/corporate-governance)[\n  * Stock Information](/investor-relations/stock-information)\n\n\n[News & Media](/news-and-media)\n\n[Working at amarin](/working-amarin)\n\n[\n  * Our Commitment](/working-amarin/our-commitment)[\n  * Open Positions](/our-commitment/open-positions)\n\n\n  * [Imprint](/imprint)\n  * | \n[Terms of Use](/terms-use)\n  * | \n[Privacy Policy](/privacy-policy)\n  * | \n[Cookie Policy](/cookie-policy)\n\n\nThis website is intended for global audiences.\n"
        }
      ]
    },
    {
      "section_name": "Analyst Coverage",
      "links": [
        {
          "title": "Analyst Coverage",
          "url": "https://amarincorp.com/investor-relations/analyst-coverage",
          "content": "You are about to review presentations, reports, filings and/or other materials regarding Amarin Corporation plc (NASDAQ: AMRN) that contain time-sensitive information.\n\nThe information contained therein is only current as of the date thereof and may not be a complete listing of all documents filed with the Securities Exchange Commission, made public or provided to Amarin shareholders.\n\nAmarin expressly disclaims any obligation to review, update or correct these materials after the date thereof. Amarin may update, amend, supplement or otherwise alter the information contained in any such materials by subsequent presentations, reports, filings, or other means without notice.\n\nCertain statements made on this web site or in materials accessed in or through the investor relations section of our web site are \"forward-looking statements,\" which are subject to risks and uncertainties, and Amarin's actual results may differ (possibly materially) from those indicated in such statements. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q.\n\nThis website is not an offer or a solicitation to buy or sell securities. Please be aware that decisions regarding investments are the responsibility of users. Although this website includes information regarding pharmaceuticals (including products under development), the information is not intended as any advertisement and/or medical advice.\n\nThis information is intended for communication with investors and should not be construed as marketing the use of any Amarin products or product candidates.\n\nInformation on this website may be revised without any prior notice.\n\nCONTINUE\n\nCANCEL\n\nGet in touch\n\nWhether you’re a patient, a healthcare professional or a job seeker, you can find the best way to contact us from the options below. We’d love to hear from you:\n\n[How to contact us](/global-login?next=%2Finvestor-relations%2Fanalyst-coverage#)\n\n[Report adverse event](/global-login?next=%2Finvestor-relations%2Fanalyst-coverage#)\n\nFollow us\n\nFollow Amarin on our social channels for the latest company news, product campaigns and industry updates:\n\n[](https://twitter.com/Amarincorp)\n\n[](https://www.linkedin.com/company/amarin-corporation/)\n\n[](https://www.youtube.com/@amarin-corporation)\n\n[About Amarin](/about-amarin)\n\n[\n  * Our Vision](/about-amarin/vision)[\n  * Our History](/about-amarin/company-history)[\n  * Where we are](/about-amarin/where-to-find-us)[\n  * Company Profile](/about-amarin/company-profile)\n\n\n[Science & Health](/science-health)\n\n[\n  * CV Health](/science-health/cv-health)[\n  * Pipeline](/science-health/our-pipeline)[\n  * Our Product](/science-health/our-product)\n\n\n[Investor Relations](/investor-relations)\n\n[\n  * Financial Information](/investor-relations/financial-information)[\n  * Analyst Coverage](/investor-relations/analyst-coverage)[\n  * Corporate Governance](/investor-relations/corporate-governance)[\n  * Stock Information](/investor-relations/stock-information)\n\n\n[News & Media](/news-and-media)\n\n[Working at amarin](/working-amarin)\n\n[\n  * Our Commitment](/working-amarin/our-commitment)[\n  * Open Positions](/our-commitment/open-positions)\n\n\n  * [Imprint](/imprint)\n  * | \n[Terms of Use](/terms-use)\n  * | \n[Privacy Policy](/privacy-policy)\n  * | \n[Cookie Policy](/cookie-policy)\n\n\nThis website is intended for global audiences.\n"
        }
      ]
    },
    {
      "section_name": "Corporate Governance",
      "links": [
        {
          "title": "Corporate Governance",
          "url": "https://amarincorp.com/investor-relations/corporate-governance",
          "content": "You are about to review presentations, reports, filings and/or other materials regarding Amarin Corporation plc (NASDAQ: AMRN) that contain time-sensitive information.\n\nThe information contained therein is only current as of the date thereof and may not be a complete listing of all documents filed with the Securities Exchange Commission, made public or provided to Amarin shareholders.\n\nAmarin expressly disclaims any obligation to review, update or correct these materials after the date thereof. Amarin may update, amend, supplement or otherwise alter the information contained in any such materials by subsequent presentations, reports, filings, or other means without notice.\n\nCertain statements made on this web site or in materials accessed in or through the investor relations section of our web site are \"forward-looking statements,\" which are subject to risks and uncertainties, and Amarin's actual results may differ (possibly materially) from those indicated in such statements. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q.\n\nThis website is not an offer or a solicitation to buy or sell securities. Please be aware that decisions regarding investments are the responsibility of users. Although this website includes information regarding pharmaceuticals (including products under development), the information is not intended as any advertisement and/or medical advice.\n\nThis information is intended for communication with investors and should not be construed as marketing the use of any Amarin products or product candidates.\n\nInformation on this website may be revised without any prior notice.\n\nCONTINUE\n\nCANCEL\n\nGet in touch\n\nWhether you’re a patient, a healthcare professional or a job seeker, you can find the best way to contact us from the options below. We’d love to hear from you:\n\n[How to contact us](/global-login?next=%2Finvestor-relations%2Fcorporate-governance#)\n\n[Report adverse event](/global-login?next=%2Finvestor-relations%2Fcorporate-governance#)\n\nFollow us\n\nFollow Amarin on our social channels for the latest company news, product campaigns and industry updates:\n\n[](https://twitter.com/Amarincorp)\n\n[](https://www.linkedin.com/company/amarin-corporation/)\n\n[](https://www.youtube.com/@amarin-corporation)\n\n[About Amarin](/about-amarin)\n\n[\n  * Our Vision](/about-amarin/vision)[\n  * Our History](/about-amarin/company-history)[\n  * Where we are](/about-amarin/where-to-find-us)[\n  * Company Profile](/about-amarin/company-profile)\n\n\n[Science & Health](/science-health)\n\n[\n  * CV Health](/science-health/cv-health)[\n  * Pipeline](/science-health/our-pipeline)[\n  * Our Product](/science-health/our-product)\n\n\n[Investor Relations](/investor-relations)\n\n[\n  * Financial Information](/investor-relations/financial-information)[\n  * Analyst Coverage](/investor-relations/analyst-coverage)[\n  * Corporate Governance](/investor-relations/corporate-governance)[\n  * Stock Information](/investor-relations/stock-information)\n\n\n[News & Media](/news-and-media)\n\n[Working at amarin](/working-amarin)\n\n[\n  * Our Commitment](/working-amarin/our-commitment)[\n  * Open Positions](/our-commitment/open-positions)\n\n\n  * [Imprint](/imprint)\n  * | \n[Terms of Use](/terms-use)\n  * | \n[Privacy Policy](/privacy-policy)\n  * | \n[Cookie Policy](/cookie-policy)\n\n\nThis website is intended for global audiences.\n"
        }
      ]
    },
    {
      "section_name": "Events and Presentations",
      "links": [
        {
          "title": "Events and Presentations",
          "url": "https://amarincorp.com/investor-relations/events-and-presentations",
          "content": "You are about to review presentations, reports, filings and/or other materials regarding Amarin Corporation plc (NASDAQ: AMRN) that contain time-sensitive information.\n\nThe information contained therein is only current as of the date thereof and may not be a complete listing of all documents filed with the Securities Exchange Commission, made public or provided to Amarin shareholders.\n\nAmarin expressly disclaims any obligation to review, update or correct these materials after the date thereof. Amarin may update, amend, supplement or otherwise alter the information contained in any such materials by subsequent presentations, reports, filings, or other means without notice.\n\nCertain statements made on this web site or in materials accessed in or through the investor relations section of our web site are \"forward-looking statements,\" which are subject to risks and uncertainties, and Amarin's actual results may differ (possibly materially) from those indicated in such statements. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q.\n\nThis website is not an offer or a solicitation to buy or sell securities. Please be aware that decisions regarding investments are the responsibility of users. Although this website includes information regarding pharmaceuticals (including products under development), the information is not intended as any advertisement and/or medical advice.\n\nThis information is intended for communication with investors and should not be construed as marketing the use of any Amarin products or product candidates.\n\nInformation on this website may be revised without any prior notice.\n\nCONTINUE\n\nCANCEL\n\nGet in touch\n\nWhether you’re a patient, a healthcare professional or a job seeker, you can find the best way to contact us from the options below. We’d love to hear from you:\n\n[How to contact us](/global-login?next=%2Finvestor-relations%2Fevents-and-presentations#)\n\n[Report adverse event](/global-login?next=%2Finvestor-relations%2Fevents-and-presentations#)\n\nFollow us\n\nFollow Amarin on our social channels for the latest company news, product campaigns and industry updates:\n\n[](https://twitter.com/Amarincorp)\n\n[](https://www.linkedin.com/company/amarin-corporation/)\n\n[](https://www.youtube.com/@amarin-corporation)\n\n[About Amarin](/about-amarin)\n\n[\n  * Our Vision](/about-amarin/vision)[\n  * Our History](/about-amarin/company-history)[\n  * Where we are](/about-amarin/where-to-find-us)[\n  * Company Profile](/about-amarin/company-profile)\n\n\n[Science & Health](/science-health)\n\n[\n  * CV Health](/science-health/cv-health)[\n  * Pipeline](/science-health/our-pipeline)[\n  * Our Product](/science-health/our-product)\n\n\n[Investor Relations](/investor-relations)\n\n[\n  * Financial Information](/investor-relations/financial-information)[\n  * Analyst Coverage](/investor-relations/analyst-coverage)[\n  * Corporate Governance](/investor-relations/corporate-governance)[\n  * Stock Information](/investor-relations/stock-information)\n\n\n[News & Media](/news-and-media)\n\n[Working at amarin](/working-amarin)\n\n[\n  * Our Commitment](/working-amarin/our-commitment)[\n  * Open Positions](/our-commitment/open-positions)\n\n\n  * [Imprint](/imprint)\n  * | \n[Terms of Use](/terms-use)\n  * | \n[Privacy Policy](/privacy-policy)\n  * | \n[Cookie Policy](/cookie-policy)\n\n\nThis website is intended for global audiences.\n"
        }
      ]
    },
    {
      "section_name": "Stock Information",
      "links": [
        {
          "title": "Stock Information",
          "url": "https://amarincorp.com/investor-relations/stock-information",
          "content": "You are about to review presentations, reports, filings and/or other materials regarding Amarin Corporation plc (NASDAQ: AMRN) that contain time-sensitive information.\n\nThe information contained therein is only current as of the date thereof and may not be a complete listing of all documents filed with the Securities Exchange Commission, made public or provided to Amarin shareholders.\n\nAmarin expressly disclaims any obligation to review, update or correct these materials after the date thereof. Amarin may update, amend, supplement or otherwise alter the information contained in any such materials by subsequent presentations, reports, filings, or other means without notice.\n\nCertain statements made on this web site or in materials accessed in or through the investor relations section of our web site are \"forward-looking statements,\" which are subject to risks and uncertainties, and Amarin's actual results may differ (possibly materially) from those indicated in such statements. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q.\n\nThis website is not an offer or a solicitation to buy or sell securities. Please be aware that decisions regarding investments are the responsibility of users. Although this website includes information regarding pharmaceuticals (including products under development), the information is not intended as any advertisement and/or medical advice.\n\nThis information is intended for communication with investors and should not be construed as marketing the use of any Amarin products or product candidates.\n\nInformation on this website may be revised without any prior notice.\n\nCONTINUE\n\nCANCEL\n\nGet in touch\n\nWhether you’re a patient, a healthcare professional or a job seeker, you can find the best way to contact us from the options below. We’d love to hear from you:\n\n[How to contact us](/global-login?next=%2Finvestor-relations%2Fstock-information#)\n\n[Report adverse event](/global-login?next=%2Finvestor-relations%2Fstock-information#)\n\nFollow us\n\nFollow Amarin on our social channels for the latest company news, product campaigns and industry updates:\n\n[](https://twitter.com/Amarincorp)\n\n[](https://www.linkedin.com/company/amarin-corporation/)\n\n[](https://www.youtube.com/@amarin-corporation)\n\n[About Amarin](/about-amarin)\n\n[\n  * Our Vision](/about-amarin/vision)[\n  * Our History](/about-amarin/company-history)[\n  * Where we are](/about-amarin/where-to-find-us)[\n  * Company Profile](/about-amarin/company-profile)\n\n\n[Science & Health](/science-health)\n\n[\n  * CV Health](/science-health/cv-health)[\n  * Pipeline](/science-health/our-pipeline)[\n  * Our Product](/science-health/our-product)\n\n\n[Investor Relations](/investor-relations)\n\n[\n  * Financial Information](/investor-relations/financial-information)[\n  * Analyst Coverage](/investor-relations/analyst-coverage)[\n  * Corporate Governance](/investor-relations/corporate-governance)[\n  * Stock Information](/investor-relations/stock-information)\n\n\n[News & Media](/news-and-media)\n\n[Working at amarin](/working-amarin)\n\n[\n  * Our Commitment](/working-amarin/our-commitment)[\n  * Open Positions](/our-commitment/open-positions)\n\n\n  * [Imprint](/imprint)\n  * | \n[Terms of Use](/terms-use)\n  * | \n[Privacy Policy](/privacy-policy)\n  * | \n[Cookie Policy](/cookie-policy)\n\n\nThis website is intended for global audiences.\n"
        }
      ]
    },
    {
      "section_name": "News & Media",
      "links": [
        {
          "title": "News & Media",
          "url": "https://amarincorp.com/news-and-media",
          "content": "Highlighting Our Actions for Cardiovascular Care\n\n![](/svg_shapes/xl_vector_shape.svg)\n\nHighlighting Our Actions for Cardiovascular Care\n\n![Medical Icons research](/_next/image?url=https%3A%2F%2Fcms.amarincorp.com%2Fsites%2Fdefault%2Ffiles%2Fstyles%2For%2Fpublic%2F2023-01%2FMedical_Icons_Phone-Desktop_0.jpg%3Fitok%3Di50H6JSi&w=3840&q=75)\n\n![](/_next/image?url=%2Fgradient_overaly.png&w=3840&q=75)\n\n[](/)\n\nNews and Media\n\nAmarin in the Media Spotlight\n\nFrom articles and press releases to social media platforms, learn about Amarin’s initiatives as we drive a new paradigm in preventative cardiovascular care.\n\nOUR LATEST NEWS\n\nFollow the links below for all the latest news from Amarin.\n\nYear\n\nAll\n\n![](https://cms.amarincorp.com/sites/default/files/styles/or/public/2022-12/inquiries.png?itok=lMU7Vt9c)\n\nMedia Contact form\n\nIf you’re a journalist or media professional, please feel free to get in touch with our media team by completing the _**contact form**_ ►  below. If you have a general or product-specific inquiry, go to the [_**contact page**_ ►](https://amarincorp.com/contact)\n\nMEDIA TOOLKIT\n\nMEDIA TOOLKIT\n\n[DOWNLOAD ALL](https://cms.amarincorp.com/sites/default/files/2024-04/Amarin_Media_Toolkit.zip)\n\n[![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%2730%27%20height=%2730%27/%3e)![Amarin Logo]()Amarin Logo](https://amaringlobalstg.prod.acquia-sites.com/sites/default/files/2023-02/Amarin%20Logo.zip)\n\n[![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%2730%27%20height=%2730%27/%3e)![Amarin Imagery]()Amarin Imagery](https://amaringlobalstg.prod.acquia-sites.com/sites/default/files/2023-02/Amarin_Imagery.zip)\n\n[![](data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%2730%27%20height=%2730%27/%3e)![Amarin Leadership team]()Amarin Leadership team](https://cms.amarincorp.com/sites/default/files/2024-04/Amarin_Leadership_Team.zip)\n\n![Amarin building ]()\n\n![Amarin building ]()\n\namarin history\n\nA Legacy of Cardiometabolic LEADERSHIP\n\nFind out how Amarin has been creating a new paradigm in cardiovascular disease management for over three decades.\n\nInvestor Relations\n\nA BOLD investment in cardiometabolic health\n\nKeeping our investors informed about our progress in helping stop cardiovascular disease from being a leading cause of death is important to us. Click here for our investor presentations, events and financial results.\n\n[LEARN MORE](/investor-relations)\n\n[![Dropper test tube ]()Science and HealthPassionate about cardiometabolic science and health Learn more about the science underpinning our product and research & development efforts to advance innovation in cardiovascular disease.](/science-health)\n\n[![Working together collaborate ]()Working at AmarinA BOLD place for entrepreneurial careersAre you interested in joining Amarin and being part of our BOLD vision to stop cardiovascular disease from being a leading cause of death worldwide? Click here for more information about our culture, career opportunities, benefits and more.](/working-amarin)\n\n![](/svg_shapes/sources-shape.svg)\n\nDISCLAIMER\n\nThe press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.\n\nALL-NP-00017 1/23\n\nGet in touch\n\nWhether you’re a patient, a healthcare professional or a job seeker, you can find the best way to contact us from the options below. We’d love to hear from you:\n\n[How to contact us](/contact)\n\n[Report adverse event](/connect-us)\n\nFollow us\n\nFollow Amarin on our social channels for the latest company news, product campaigns and industry updates:\n\n[](https://twitter.com/Amarincorp)\n\n[](https://www.linkedin.com/company/amarin-corporation/)\n\n[](https://www.youtube.com/@amarin-corporation)\n\n[About Amarin](/about-amarin)\n\n[\n  * Our Vision](/about-amarin/vision)[\n  * Our History](/about-amarin/company-history)[\n  * Where we are](/about-amarin/where-to-find-us)[\n  * Company Profile](/about-amarin/company-profile)\n\n\n[Science & Health](/science-health)\n\n[\n  * CV Health](/science-health/cv-health)[\n  * Pipeline](/science-health/our-pipeline)[\n  * Our Product](/science-health/our-product)\n\n\n[Investor Relations](/investor-relations)\n\n[\n  * Financial Information](/investor-relations/financial-information)[\n  * Analyst Coverage](/investor-relations/analyst-coverage)[\n  * Corporate Governance](/investor-relations/corporate-governance)[\n  * Stock Information](/investor-relations/stock-information)\n\n\n[News & Media](/news-and-media)\n\n[Working at amarin](/working-amarin)\n\n[\n  * Our Commitment](/working-amarin/our-commitment)[\n  * Open Positions](/our-commitment/open-positions)\n\n\n  * [Imprint](/imprint)\n  * | \n[Terms of Use](/terms-use)\n  * | \n[Privacy Policy](/privacy-policy)\n  * | \n[Cookie Policy](/cookie-policy)\n\n\nThis website is intended for global audiences.\n"
        }
      ]
    }
  ]
}